Morphea: a practical review of its diagnosis, classification and treatment

Pamela Rodríguez-Salgado and María Teresa García-Romero*

Instituto Nacional de Pediatría, Dermatology Department, Mexico City, Mexico

Abstract

Morphea, or localized scleroderma, is a rare disease of the connective tissue that manifests itself with localized sclerosis of the skin and, in some cases, with extracutaneous manifestations. Its etiology is not fully understood, but it is believed that there is genetic predisposition, in addition to environmental triggering factors. Classification of the disease is not simple due to its multiple presentations; however, it is useful in order to define the treatment, which should be individualized and started early to avoid cosmetic and functional complications. In this review, we summarize the most important practical aspects of the classification, diagnostic methods and evaluation of morphea activity, as well as available therapeutic options, with an emphasis on existing clinical evidence regarding their efficacy and safety.

KEY WORDS: Morphea. Localized scleroderma. Lichen sclerosus et atrophicus.

Introduction

Morphea, also known as localized scleroderma, is a chronic inflammatory disease of the dermis and subcutaneous cellular tissue in which a sclerotic process with diffuse thickening and induration of the skin is generated, as well as atrophy at various levels.¹⁻³ Usually, its evolution is benign; however, 10 % of patients suffer severe sclerosis and atrophy, which can cause deformity, contractures or growth disorders.^{2,3}

Morphea is considered an entity that is different to systemic sclerosis and does not evolve into it, although both share physiopathogenic factors. Often, patients with morphea can have extracutaneous involvement, mainly ocular, articular and central nervous system compromise.²

Diagnosis and management of patients with morphea is not always easy and can be a challenge for the dermatologist. In this article, the basic concepts of the disease are reviewed, with special focus on the diagnosis, classification and treatment.

Basic concepts

Morphea is relatively uncommon, with an annual incidence of 2.7 per 100,000 population.⁴ It predominates in women, with a ratio of 2.6:1;^{5,6} and although it affects all ethnicities, it predominates in the Caucasian population. In 75 to 90 % of patients it occurs between the ages of 20 and 50 years.¹ It is possible that due to the delay in diagnosis, the true prevalence of morphea is underestimated.³

Morphea etiology and pathogenesis are not yet fully understood. Autoimmune, environmental factors and various events that trigger the production of cytokines are thought to be involved, including infections, radiation or trauma.^{3,7} *Borrelia burgdorferi* infection might have a pathogenic role; however, a causal association has not been confirmed.⁷ There is an unproven hypothesis that morphea may be due to post-cygotic mosaicism by the blaschkoid or dermatomic distribution of many lesions⁸ (Fig. 1).

Correspondence:

*María Teresa García-Romero
E-mail: teregarro@gmail.com

Date of reception: 07-03-2018

Date of acceptance: 19-11-2018

DOI: 10.24875/GMM.M20000336

Gac Med Mex. 2019;155:483-491

Contents available at PubMed

www.gacetamedicademexico.com

0016-3813/© 2018 Academia Nacional de Medicina de México, A.C.. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Figure 1. Patient with generalized morphea, with multiple indurated and hyperpigmented plaques with blaschkoid distribution.

The skin sclerosis process comprises three main events, which can be therapeutic targets:

- A primary microvascular lesion, with SVCAM-1 and sE-selectin elevation, which are indicators of endothelial activation; as well as expression of adhesion molecules, thickening of the basement membrane and intimal hyperplasia.⁹
- Fibroblast function control by perivascular CD4+ T cells that produce interleukin-4 and transforming growth factor β , which are cytokines that direct differentiation towards the Th2 phenotype, recruit eosinophils (which can be found at morphea early stages) and modify the synthesis of collagen by fibroblasts.¹⁰
- Pathological production of collagen (I, II, III) by fibroblasts, as well as other extracellular matrix proteins.³

Classification and clinical presentation

Morphea includes a variety of conditions where the skin or subcutaneous cell tissue are affected by sclerosis. Classification can guide the treatment and prognosis; however, it is not simple, because the different

Figure 2. A) Erythematous edematous plaque in the paramedial line of the face that corresponds to an initial linear morphea lesion. B) The same lesion several months later, where sclerosis, atrophy and loss of annexes is evident.

types are not always clear and overlap.¹¹ The current accepted classification is detailed in Table 1.¹²

Morphea can affect any part of the body and is characterized by one or several well-defined plaques of varying sizes of thickened, bright, atrophic skin; either hyper or hypopigmented. The lesions begin insidiously as erythematous-edematous or violet plaques that spread centrifugally; they are usually asymptomatic and go unnoticed by the patient. As they evolve, they start to become sclerotic, indurated tissue, acquire a bright white color and, in the periphery, violet rings are appreciated, which disappear when progression of the lesion stops and give rise to residual pigmentary changes (Fig. 2). They evolve chronically until atrophy reaches various levels: epidermis, dermis or subcutaneous cellular tissue. Sometimes, different clinical forms are combined in one single patient. Activity of the lesions lasts from three to five years, with a tendency to remission; however, there may be recurrences. In children, more severe, mutilating and disabling forms occur, such as disabling pan-sclerotic morphea of childhood.^{3,13,14}

Linear morphea is the most common variant during childhood or adolescence; it begins at this stage in 40 to 70 % of patients.¹¹ It mainly affects the extremities, the head in the frontal area (morphea en coup de sabre) (Fig. 2) and the chest. It is accompanied by loss of adnexal structures, pruritus and xerosis. Nearly 50 %¹ of patients with this type of morphea also have plaque lesions (mixed morphea), which is common in children and rare in adults.^{5,6,15} Up to 30 % of patients with linear morphea can experience extracutaneous involvement with ophthalmological or neurological disorders such as migraines, headaches, seizures or uveitis; or musculoskeletal disorders in patients with limb involvement.^{15,16}

Table 1. Current classification of morphea according to the European Society of Pediatric Rheumatology, 2004⁶⁹

Subtype	Modality	Clinical characteristics
Circumscribed or plaque morphea	Superficial	Single or multiple round- or oval-shaped lesions limited to the epidermis and dermis.
	Deep	Single or multiple round- or oval-shaped lesions that involve subcutaneous, fascia or muscle.
Linear morphea	Trunk/extremities	Linear lesions involving the dermis and subcutaneous or deep tissue.
	Head	Linear lesions in the head, may involve underlying bone; either "en coup de sabre" type or progressive hemifacial atrophy.
Generalized morphea		4 or more plaques, in 2 or more anatomical sites.
Disabling pan-sclerotic morphea of childhood		Circumferential lesion of most of the body surface area (sparing finger and toe tips) that affects the skin, subcutaneous cell tissue, muscle or bone. No visceral involvement.
Mixed morphea		Combination of any of the subtypes.

Figure 3. Plaque morphea in the trunk. Epidermal and dermal superficial atrophy with visible vessels.

Circumscribed or plaque morphea is the most common type in adults and the most superficial form due to the limitation of the fibrotic process to the dermis. It is characterized by circumscribed or oval, single or multiple, 1- to 30-cm sclerotic plaques (Fig. 3).^{3,13}

Generalized morphea is a severe form of the disease, defined as four or more plaques larger than 3 cm that converge and involve more than two anatomical sites (Fig. 1). It occurs in 7 to 9 % of patients with morphea and is characterized by rapid plaque spread.¹³ It is usually not associated with extracutaneous manifestations.¹¹

Pan-sclerotic morphea (also called childhood disabling morphea) is an aggressive and mutilating variant that most often affects children. Presentation is rapidly progressive and deteriorates deep structures such as muscles, tendons and bone by generating joint contractions, painful ulcerations and calcifications that lead to significant disability (Fig. 4).^{14,17}

Figure 4. Pan-sclerotic morphea of childhood in left lower extremity. Note the circumferential and deep involvement of sclerosis and atrophy.

Some less common variants of morphea are described in Table 2.^{3,5,14,16,18,19}

Diagnosis

The diagnosis of morphea is mainly clinical, through history and careful physical examination of the skin. The interrogation of the patient about evolution of the lesions or comparison with previous photographs is quite helpful, as well as identifying the different morphology patterns: plaque or circumscribed, linear, generalized, superficial or deep.¹⁹⁻²²

Laboratory tests

Laboratory tests are not considered necessary for the diagnosis or follow-up of patients with morphea. Erythrocyte sedimentation rate and blood count are within normal ranges in most cases, but eosinophilia may appear, especially at early stages of the disease. The presence of antinuclear antibodies or anti-double-stranded anti-DNA and anti-histone antibodies

Table 2. Morphea less common variants^{1,11,19}

Morphea guttata	Sclero-atrophic whitish small lesions that lack the firm characteristics of morphea, with dilated follicular orifices.
Nodular (keloid) morphea	Nodular lesions resembling keloids.
Atrophoderma	Multiple subtly depressed, oval-shaped and hyperpigmented plaques appear on the trunk and upper limbs, without the presence of sclerosis.
Parry-Romberg syndrome or progressive facial hemiatrophy	Uniform atrophy of the dermis, subcutaneous and muscular cellular tissue and, in some cases, bone, in a hemifacial or trigeminal distribution. It is associated with neurological symptoms in up to 30% of cases.
Eosinophilic fasciitis or Shulman syndrome	Of sudden onset, with bilateral painful induration exclusively of the extremities. It is accompanied by peripheral eosinophilia and increased erythrocyte sedimentation. It is rare in childhood.
Lichen sclerosus et atrophicus	White or pale purple-colored atrophic plaques with a shiny appearance. It frequently affects the anogenital area, but can occur in any area of the body. Associated with circumscribed and generalized morphea.

occurs in approximately 30% of patients, mainly in those with linear or generalized morphea.^{5,6,13,15,23}

Due to the frequency of extracutaneous alterations, especially in patients with linear morphea, it is important to deliberately look for them through patient interrogation and consultation with the ophthalmology, neurology or orthopedics departments, in addition to relevant paraclinical tests. Some authors recommend performing brain magnetic resonance imaging and routine ophthalmological examination in patients with linear morphea in the head.¹⁶

Histopathology

Morphea histology depends on two factors: the stage of the disease and the depth to which it extends. At early stages, perivascular lymphocytic inflammatory infiltrate, endothelial edema and, sometimes, eosinophils, plasma cells and mast cells are found, as well as skin appendageal atrophy and vessels with thickened walls and narrow lumen (Fig. 5).²⁴ At later stages, the inflammatory infiltrate decreases or disappears, and loss of appendages, flattened dermo-epidermal junction and collagen bundles in the reticular dermis are observed, with a packaged appearance and alignment parallel to the dermo-epidermal junction.²⁴ Deep morphea primarily affects the subcutaneous cellular tissue,

Figure 5. Morphea histological image, with dermal collagen hyalinization, loss of appendages and mixed inflammatory infiltrate are observed.

Table 3. Useful characteristics and factors to assess morphea activity and severity^{27,30}

Appearance of new lesions or expansion of existing lesions in the last 3 months.
Erythema or moderate or severe edema in the lesions.
Erythema/violet borders of lesions.
Induration or progressive increase or sclerosis in the lesion.
Hair-loss associated with the lesions.
Documentation by the physician of disease activity or progression to deep tissues, through activity scales, photographs, magnetic resonance imaging or ultrasound.
Skin biopsy demonstrating disease activity.

and produces extensive sclerosis and hyalinization, which extends to the underlying fascia.²⁵

Evaluation of morphea activity and severity

Assessing the activity of the disease is extremely important for making therapeutic decisions; however, it is not always easy, since currently there are no objective, clear or objective standardized outcome measures.²⁶ The factors and characteristics referred to in Table 3 may be helpful in determining the activity of a morphea plaque.^{1,3,27}

Some scales have been developed to assess disease activity, such as the Localized Scleroderma Severity Index (LoSSI) and the Localized Scleroderma Damage Index (LoSDI); together, they make up the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT), which has been validated (Table 4).^{28,29} The DIET scale is another tool that has been proposed to assess morphea plaque; however, it has not been validated (Table 5).²⁷

Table 4. Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)

mLoSSI (Modified Localized Scleroderma Skin Activity Index)			LoSDI (Localized Scleroderma Skin Damage Index)		
New lesion or growth (within previous month) 0 = No 3 = Yes	Erythema 0 = No 1 = Pink 2 = Red 3 = Dark red/Violet	Thickening 0 = No 1 = Slight 2 = Moderate 3 = Severe	Dermal atrophy 0 = No 1 = Shiny surface 2 = Visible blood vessels 3 = "Cliff-drop" sign	Subcutaneous atrophy 0 = No 1 = Flat 2 = Concave 3 = Severe atrophy	Depigmentation 0 = No 1 = Mild 2 = Moderate 3 = Severe
0-3	0-3	0-3	0-3	0-3	0-3

A score from 0 to 3 should be assigned for each one of the 6 items. Highest score: 18.

Table 5. DIET scale (depigmentation, induration, erythema and telangiectasia)

Depigmentation (hypo or hyper)	0-3
Induration	0-3
Erythema	0-3
Telangiectasia	0-3

A score of 0 to 3 should be subjectively assigned to each one of the 4 items.
Highest score: 12.

Table 6. Topical treatments for morphea

Treatment	Level of evidence*	Grade of recommendation*
5% imiquimod ⁴⁰	1b	B
Tacrolimus ³⁹	1b	B
Pirfenidone ⁴³	4	C
Calcipotriol ⁴²	4	C
Calcipotriol/betamethasone dipropionate ⁴¹	4	C
Calcipotriol/PUVA cream ⁷⁰	5	D

PUVA = psoralen+phototherapy with ultraviolet light A.

*Highest level of evidence according to the Centre for Evidence-Based Medicine, Oxford (Appendix 1).

There is significant correlation between the different morphea activity scales (LoSSI, LoSCAT, DIET) and even with a visual analog or subjective scale of lesion activity from the physician's and patient's point of view;²⁷ therefore, it is acceptable to use the more practical to assess patients.

Other tools proposed to assess morphea activity include the durometer (which evaluates skin thickness), a computed scale that calculates the exact area of induration, Doppler ultrasound and infrared thermography.³⁰

Treatment

Morphea treatment can be a challenge, since there is no medication considered to be the gold standard. In addition, the choice of treatment will depend on

how active the disease is, its extent, localization, depth and progression; i.e., it will be individualized to each patient (Fig. 1).²⁶ Treatment should be started early, before the appearance of complications in patients with risk associated with the morphea characteristics.³¹ It is recommended for treatment to continue until the disease activity disappears, even if atrophy and depigmentation do not completely improve.^{1,11,19,22,32-36}

Topical treatment

Topical treatment is limited to the superficial and circumscribed varieties of morphea, without any movement or growth restriction.^{26,37} Therapeutic options, the level of evidence and the strength of recommendation are listed in Table 6:

- Tacrolimus (0.1 %): calcineurin inhibitor, with good effectiveness and safety.^{38,39}
- Imiquimod: immunomodulator that regulates interferon (IFN) α and γ and inhibits the production of collagen by fibroblasts by negatively regulating transforming growth factor β . It is particularly effective in indurated lesions.⁴⁰
- Calcipotriol: vitamin D-derived, inhibits fibroblast proliferation in vitro; it is clinically effective alone and combined with betamethasone dipropionate.^{41,42}

Other anecdotally used medications and in small series of patients with apparent benefit are pirfenidone and subcutaneous immunoglobulin.^{25,43} Intraleisional IFN γ has been shown not to be effective with good evidence (level 1b).⁴⁴

Topical steroids, used by more than 90% of doctors, have not been formally studied.³⁶

Systemic treatment

It should be used in linear morphea in the head and extremities with potential functional or cosmetic disability, in generalized or rapidly progressive lesions and in pan-sclerotic morphea.^{1,3,11,19,21,22,26,32-35,37,45,46} Therapeutic

Table 7. Systemic treatments for morphea

Treatment	Level of evidence*	Grade of recommendation*
Methotrexate ⁴⁷	1b	A
LD UVA1 ⁵⁷	1b	A
MD UVA1 ⁵⁷	1b	A
HD UVA1 ⁵⁷	2b	B
LD UVA1/calcipotriol	2b	B
NB UVB ⁵⁷	2b	B
Fractionated CO ₂ laser versus LD UVA1 ⁷¹	2b	B
Oral PUVA ⁷²	4	C
Bath/topical PUVA ⁵⁸	4	C
Abatacept ⁷³	4	C
Cyclosporine ⁷⁴	4	C
Mycophenolate mofetil ^{75,76}	4	C
Tocilizumab ⁷⁷	4	C
PUVA/retinoic acid	4	C
D-penicillamine ⁷⁸	4	C
Imatinib ^{79,80}	5	D
Methotrexate+excimer laser ⁸¹	5	D
Leflunomide/infliximab ⁸²	5	D
Etretinate ⁸³	5	D
EC photopheresis+BB UVA ⁸⁴	5	D

CO₂ = carbon dioxide, UVA1 = phototherapy with ultraviolet A1 light (LD = low dose, less than 30 J/cm², MD = medium dose, 50-70 J/cm², HD = high dose, 130 J/cm²), NB UVB = phototherapy with narrow band ultraviolet B light, PUVA = psoralen+phototherapy with ultraviolet A light, EC = extracorporeal, BB UVA = phototherapy with broadband ultraviolet A light.

*According to the Centre for Evidence-Based Medicine, Oxford (Appendix 1).

options, the level of evidence and the strength of recommendation are listed in Table 7; the most efficacious are the following:

- Methotrexate: tetrahydrofolate reductase inhibitor. It is the drug with most evidence regarding its effectiveness in morphea and is currently considered the first line treatment, with or without systemic corticosteroids for a short period of time (prednisone 0.5-1 mg/kg/day) or in pulses (intravenous methylprednisolone 1-2 mg/kg/day for three days each month for three months). Methotrexate should be continued for at least 12 to 18 months and be discontinued until six months have elapsed without disease activity.⁴⁷⁻⁵¹
- Phototherapy: with ultraviolet (UV) light A1, UV B or with psoralen (PUVA) the course of disease is

altered, with resolution or marked improvement in patients. It induces the expression of metalloproteinase 1, a collagenase that reduces procollagen and collagen in the skin and is effective in all morphea subtypes. UVA1 at different doses (low, medium and high) and broadband UVA have been found to be effective, although the benefit with regard to the risk of oral, bath or topical PUVA is less clear.⁵²⁻⁵⁹ Narrowband UVB has also been shown to be effective and to have a very good safety profile.⁵⁷

There is evidence that prednisone as monotherapy (level 2b)⁴⁷ and oral calcitriol 1,25 dihydroxyvitamin D3 (level 1b)^{60,61} are not effective treatments.

Physical therapy

Physiotherapy is mandatory in patients in whom morphea causes mobility alterations or disability it is considered part of the treatment in patients with linear morphea in extremities or extensive lesions, to preserve the degree of mobility and minimize contractures, although its effectiveness has never been studied.³⁵

Surgical or cosmetic treatment

Once the disease is inactive without treatment for at least one or two years and children have reached full growth, residual damage can be treated in various forms such as plastic surgery, lipoinplants, filling material or fatty tissue-free flaps.⁶²⁻⁶⁵ The goal of surgical treatment is specifically volume restoration, since asymmetry is one of patients' main concerns.⁶⁶ Orthopedic surgery may be indicated if patients develop joint and bone deformity as sequelae of linear or deep morphea, including the release of joint contractures and limb lengthening procedures.^{67,68}

Prognosis

The prognosis of circumscribed or superficial morphea is good, although the disease shows a tendency towards progression. Generally, the disease is inactivated in between three and five years, but approximately 30 % of patients will experience relapses,³⁸ especially if morphea started in childhood and if treatment was not adequate. The linear and deep forms can leave important sequelae with functional and esthetic disability.

Conclusions

Morphea is an inflammatory disease of common onset in childhood and predominance in females, where localized sclerosis of the skin and underlying tissue occurs. Its pathophysiology is not fully understood; however, it is known that there is initial microvascular damage and abnormal T-lymphocyte response, which generates abnormal collagen production and fibrosis. In some cases, its classification is difficult, but lesion location and the degree of potential disability that the disease can generate in the patient should always be considered in order to choose the treatment, which should be individualized and promptly started. Topical treatment is preferred for circumscribed or localized forms; tacrolimus and imiquimod are the most recommended options. Systemic therapy is the treatment of choice for linear or severe forms; methotrexate and phototherapy with UVA1 are considered the first-line options. Approximately 30 % of patients with linear morphea may have extracutaneous, neurological, articular or ophthalmological lesions, which should be deliberately searched and discarded.

References

- Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. *An Bras Dermatol*. 2015;90:62-73.
- García de la Peña-Lefebvre P. Esclerodermia localizada. *Protoc Diagn Ter Pediatr*. 2014;1:1-6.
- García-Romero M, Laxer RM, Pope E. Localized scleroderma: symptoms, diagnosis and treatment. En: De Winter R, editor. *Scleroderma symptoms, diagnosis and treatment*. EE. UU.: Nova Science Publishers; 2013.
- Peterson L, Nelson A, Su W, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. *J Rheumatol*. 1997; 24:73-80.
- Zulian F, Athreya BH, Laxer RM, Nelson AM, Feitosa-De Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. *Rheumatology (Oxford)*. 2006;45:614-620.
- Christen-Zaech S, Hakin MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. *J Am Acad Dermatol*. 2008;59:385-396.
- Alfaro-Cordero K. Morfea: el desequilibrio entre la producción y la destrucción del colágeno. *Rev Med Cos*. 2016;73:351-354.
- Paller AS. Piecing together the puzzle of cutaneous mosaicism. *J Clin Invest*. 2004;114:1407-1409.
- Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. *J Am Acad Dermatol*. 2000;42:64-69.
- Serpier H, Gillery P, Salmon-Ehr V, Garnotel R, Georges N, Kalis B, et al. Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures. *J Invest Dermatol*. 1997;109:158-162.
- Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. *Acta Dermosifiliogr*. 2013;104:654-666.
- Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA, Lehman TJ, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League Against Rheumatism Provisional Classification Criteria for Juvenile Systemic Sclerosis. *Arthritis Rheum*. 2007; 57:203-212.
- Noguera M, Sauro-De Carvalho M, Lombardi V. Morfea. *Arch Argent Dermatol*. 2012;62:77-84.
- Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. *Curr Opin Rheumatol*. 2013;25:643-650.
- Pequet M, Holland KE, Zhao S, Drolet BA, Galbraith SS, Siegel DH, et al. Risk factors for morphea disease severity: a retrospective review of 114 paediatric patients. *Br J Dermatol*. 2014;170:895-900.
- Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. *Pediatr Dermatol*. 2012;29:738-748.
- Kim A, Marinkovich N, Vásquez R, Jacobe HT. Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort. *J Rheumatol*. 2014;41:106-112.
- Kreuter A, Wischniewski J, Terras S, Altmeyer P, Stücker M, Gambichler T. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. *J Am Acad Dermatol*. 2012;67:1157-1162.
- Pope E, Laxer RM. Diagnosis and management of morphea and lichen sclerosus and atrophicus in children. *Pediatr Clin North Am*. 2014;61:309-319.
- Fett NM. Morphea (localized scleroderma). *JAMA Dermatol*. 2013; 149:1124.
- Knobler R, Moizadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European Dermatology Forum S1-Guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes. *J Eur Acad Dermatol Venerol*. 2017;31:1401-1424.
- Kreuter A, Krieg T, Worm M, Wenzel J, Moizadeh P, Kuhn A, et al. German guidelines for the diagnosis and therapy of localized scleroderma. *J German Soc Dermatol*. 2016;14:199-216.
- Chiu YE. Practice gaps: evaluating the clinical utility of autoantibodies in morphea. *JAMA Dermatol*. 2013;149:1166.
- Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: results from the morphea in adults and children cohort V. *J Am Acad Dermatol*. 2017;76:1124-1130.
- Yamazaki-Nakashimada MA, Saez-De Ocariz M, Maldonado-Colín G, García-Romero MT. Subcutaneous immunoglobulin for the treatment of deep morphea in a child. *Clin Exp Dermatol*. 2017;43:303-305.
- Zwischenberger B, Jacobe H. A systematic review of morphea treatments and therapeutic algorithm. *J Am Acad Dermatol*. 2011;65:925-941.
- García-Romero MT, Laxer RM, Pope E. Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. *Br J Dermatol*. 2015;174:408-410.
- Arkachaisri T, Vilaiyuk S, Li S, O'Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. *J Rheumatol*. 2009;36:2819-2829.
- Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. *Rheumatology (Oxford)*. 2010;49:373-381.
- García-Romero MT, Randhawa HK, Laxer RM, Pope E. The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. *Int J Dermatol*. 2016;56:63-67.
- Khan MA, Shaw L, Eleftheriou D, Prabhakar P, Chong WK, Glover M, et al. Radiologic improvement after early medical intervention in localised facial morphea. *Pediatr Dermatol*. 2016;33:e95-e98.
- Brady SM, Shapiro L, Mousa SA. Current and future direction in the management of scleroderma. *Arch Dermatol Res*. 2016;308:461-471.
- Hawley DP, Pain CE, Baildam EM, Murphy R, Taylor AE, Foster HE. United Kingdom survey of current management of juvenile localized scleroderma. *Rheumatology (Oxford)*. 2014;53:1849-1854.
- Warburton KL, McPhee MJ, Savage LJ, Honan AE, Montgomery R, Ghazavi M, et al. Management of morphea: results of a national survey of U.K. clinicians. *Br J Dermatol*. 2014;171:1243-1245.
- Fett NM, Werth VP. Update on morphea: part II. Outcome measures and treatment. *J Am Acad Dermatol*. 2011;64:231-242.
- Strickland N, Patel G, Strickland A, Jacobe H. Attitudes and trends in the treatment of morphea: a national survey. *J Am Acad Dermatol*. 2015; 72:727-728.
- Kreuter A, Altmeyer P, Gambichler T. Treatment of localized scleroderma depends on the clinical subtype. *Br J Dermatol*. 2007;156:1363-1364.
- Piram M, McCuaig CC, Saint-Cyr C, Marcoux D, Hatami A, Haddad E, et al. Short- and long-term outcome of linear morphea in children. *Br J Dermatol*. 2013;169:1265-1271.
- Kroft EB, Groeneveld TJ, Seyger MM, De Jong EM. Efficacy of topical tacrolimus 0.1 % in active plaque morphea: randomized, double-blind controlled pilot study. *Am J Clin Dermatol*. 2009;10:181-187.
- Dytoc M, Wat H, Cheung-Lee M, Sawyer D, Ackerman T, Fiorillo L. Evaluation of the efficacy and safety of topical imiquimod 5 % for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial. *J Cut Med Surg*. 2015;19:132-139.
- Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol-betaethasone dipropionate for morphea. *Br J Dermatol*. 2007; 157:615-618.
- Tay YK. Topical calcipotriol ointment in the treatment of morphea. *J Dermatolog Treat*. 2003;14:219-221.
- Rodríguez-Castellanos M, Tlacuilo-Parra A, Sánchez-Enríquez S, Vélez-Gómez E, Guevara-Gutiérrez E, et al. Pifendione gel in patients with localized scleroderma: a phase II study. *Arthr Res Ther*. 2015;16:510.

44. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. *J Am Acad Dermatol*. 1997;36:433-435.
45. Li S, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. *Arth Care Res (Hoboken)*. 2012;64:1175-1185.
46. Tratenberg M, Gutwein F, Rao V, Sperber K, Wasserman A, Ash J. Localized scleroderma: a clinical review. *Curr Rheumatol Rev*. 2017;13:86-92.
47. Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2011;63:1998-2006.
48. Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). *J Am Acad Dermatol*. 2012;67:1151-1156.
49. Rattanakaemakorn P, Jorizzo J. The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype). *J Dermatol Treat*. 2017;29:197-199.
50. Uziel Y, Feldman B, Krafchik B, Yeung RS, Laxer RM. Methotrexate and corticosteroids therapy for pediatric localized scleroderma. *J Pediatr*. 2000;136:91-95.
51. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JL. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphea) in children. *Br J Dermatol*. 2006;155:1013-1020.
52. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. *BMC Dermatol*. 2004;4:11.
53. De Rie MA, Enomoto DN, De Vries H, Bos JD. Evaluation of medium-dose UVA-1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. *Dermatology*. 2003;207:298-301.
54. El-Mofty M, Mostafa W, El-Darouty M, Bosseila M, Nada H, Yousef R, et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. *Photodermatol Photoimmunol Photomed*. 2004;20:148-156.
55. El-Mofty M, Zaher H, Bosseila M, Yousef R, Saad B. Low-dose broad-band UVA in morphea using a new method for evaluation. *Photodermatol Photoimmunol Photomed*. 2000;16:43-49.
56. Keyal U, Bhatta AK, Wang XL. UVA1 a promising approach for scleroderma. *Am J Transl Res*. 2017;9:4280-4287.
57. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA-1, medium-dose UVA-1 and narrowband UVB phototherapy in the treatment of localized scleroderma. *J Am Acad Dermatol*. 2006;54:440-447.
58. Pavlotsky F, Sakka N, Lozinski A, Barzilai A. Bath psoralen-UVA photochemotherapy for localized scleroderma: experience from a single institute. *Photodermatol Photoimmunol Photomed*. 2013;29:247-252.
59. Vázquez R, Jabbar A, Khan F, Buethe D, Ahn C, Jacobe H. Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study. *J Am Acad Dermatol*. 2014;70:481-488.
60. Elst EF, Van Suijlekom-Smit L, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. *Pediatric Dermatol*. 1999;16:53-58.
61. Hulshof MM, Bouwes-Bavinck JN, Bergman W, Masclee AA, Heikendorff L, Breedveld FC, et al. Double-blind, placebo controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. *J Am Acad Dermatol*. 2000;43:1017-1023.
62. Barin EZ, Cinal H, Cakmak MA, Tan O. Treatment of linear scleroderma (en coup de sabre) with dermal fat grafting. *J Cutan Med Surg*. 2016;20:269-271.
63. Pimenta de Araujo-Franco J, Soares-Serra M, Barbosa-Lima R, Macedo-D'Acri A, Martins CJ. Scleroderma en coup de sabre treated with polymethylmethacrylate. Case report. *An Bras Dermatol*. 2016;91:209-211.
64. Iblor KS, Gramkow C, Siemssen PA. Autologous fat transplantation for the treatment of linear scleroderma en coup de sabre. *Skinmed*. 2015;13:74-76.
65. Rimoim L, Arbiser J. Improvement of en coup de sabre morphea and associated headaches with botulinum toxin injections. *Dermatol Surg*. 2016;42:1216-1219.
66. Íñigo F, Jiménez-Murat Y, Arroyo O, Fernández M, Ysunza A. Restoration of facial contour in Romberg's disease and hemifacial microsomia: experience with 118 cases. *Microsurgery*. 2000;20:167-172.
67. Palmero ML, Uziel Y, Laxer RM, Forrest CR, Pope E. En coup de sabre scleroderma and Parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes. *J Rheumatol*. 2010;37:2174-2179.
68. Schoch JJ, Schoch BS, Werthel JD, McIntosh AL, Davis DMR. Orthopedic complications of linear morphea: implications for early interdisciplinary care. *Pediatr Dermatol*. 2018;35:43-46.
69. Laxer RM, Zulian F. Localized scleroderma. *Curr Opin Rheumatol*. 2006;18:606-613.
70. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. *J Am Acad Dermatol*. 2000;43:675-678.
71. Shalaby SM, Bosseila M, Fawzy MM, Abdel Halim DM, Sayed SS, Allam RS, et al. Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study. *Laser Med Sci*. 2016;31:1707-1715.
72. Usmani N, Murphy A, Veale D, Goulden V, Goodfield M, et al. Phototherapy for localized morphea: effect on clinical and molecular markers. *Clin Exp Dermatol*. 2008;33:698-704.
73. Adeeb F, Anjum S, Hodnett P, et al. Early- and late-stage morphea subtypes with deep tissue involvement is treatable with abatacept (Orencia). *Semin Arthr Rheumatism*. 2017;46:775-781.
74. Bali G, Fruhauf J, Wutte N, et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review. *Dermatology (Basel, Switzerland)*. 2016;232:503-510.
75. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. *Rheumatol (Oxford)*. 2009;48:1410-1413.
76. Mertens JS, Marsman D, Van de Kerkhof PC, Hoppenreijns EP, Knaapen HK, Radstake TR, et al. Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate. *Acta Derm Venereol*. 2016;96:510-513.
77. Martini G, Campus S, Raffener B, Boscarol G, Meneghel A, Zulian F. Tocilizumab in two children with pansclerotic morphea: a hopeful therapy for refractory cases? *Clin Exp Rheumatol*. 2017;106:211-213.
78. Kaur S, Dhar S, Kanwar AJ. Treatment of childhood linear morphea with D-penicillamine. *Pediatr Dermatol*. 1993;10:201-202.
79. Alcántara-Reifs CM, Garnacho-Saucedo GM, Salido-Vallejo R, De la Corte-Sánchez S, García-Nieto AV. Imatinib treatment of therapy resistant generalized deep morphea. *Dermatol Ther*. 2015;28:271-273.
80. Coelho-Macías V, Mendes-Bastos P, Assis-Pacheco F, Cardoso J. Imatinib: a novel treatment approach for generalized morphea. *Int J Dermatol*. 2014;53:1299-1302.
81. Hanson AH, Fiverson DP, Schapiro B. Linear scleroderma in an adolescent woman treated with methotrexate and excimer laser. *Dermatol Ther*. 2014;27:203-205.
82. Ferguson ID, Weiser P, Torok KS. A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. *Open Rheumatol J*. 2015;9:30-35.
83. Shima T, Yamamoto Y, Ikeda T, Furukawa F. A patient with localized scleroderma successfully treated with etretinate. *Case Rep Dermatol*. 2014;6:200-206.
84. Pileri A, Raone B, Raboni R, Giudice V, Patrizi A. Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP). *Dermatol Online J*. 2014;20:21258.
85. Howick J, Chalmers I, Glasziou. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence. EE. UU.: Oxford Centre for Evidence-Based Medicine; 2011.
86. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. EE. UU.: Oxford Centre for Evidence-Based Medicine; 2009.

Appendix

Appendix 1. Levels of evidence and grade of recommendation according to Oxford's Centre for Evidence-Based Medicine^{85,86}

Level of evidence	Type of study
1a	Systematic reviews (with homogeneity) of randomized controlled trials.
1b	Individual randomized controlled trials (with narrow confidence interval).
1c	All or none randomized controlled trials.
2a	Systematic reviews (with homogeneity) of cohort studies.
2b	Individual cohort study or low-quality randomized controlled trials (> 80% exclusion of the sample).
2c	Outcomes research; ecological studies.
3a	Systematic review (with homogeneity) of case-control studies.
3b	Individual case-control study.
4	Case series (and poor quality cohort and case-control studies).
5	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles".
Grades of recommendation	Meaning
A	Consistent level 1 studies (more than 1)
B	Consistent level 2 or 3 studies, or extrapolation from level 1 studies
C	Level 4 studies or extrapolations from level 2 or 3 studies.
D	Level 5 studies or troublingly inconsistent or inconclusive studies of any level.